FSD Pharma: Rupert Haynes
The pharmaceutical company announced the appointment of Rupert Haynes as CEO, after his near three decades of service in the industry. Interim CEO and co-chairman of the board, Raza Bokhari, will remain in place until Haynes assumes the role.
Haynes previously held the position of head of global marketing at GW Pharmaceuticals in the UK. In this position, he supervised the development of the firms’ cannabinoid portfolio. He also worked to plan and develop Epidiolex, an FDA-approved cannabidiol for the treatment of seizures.
Previous to his work at GW, Haynes held various commercial roles across the industry, including at Sobi, UCB Pharma, Bristol-Meyers Squibb, and Pharmacia & Upjohn.
Bokhari stated that Haynes, “blends world class specialty pharmaceutical experience with a fast-paced biotech mindset that will help accelerate FSD’s growth and global expansion strategy.”
